Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP252058.RAUL-FYGd_siR69BPKVa6AMlovCN2Rjfz7avy_MrAC0QQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP252058.RAUL-FYGd_siR69BPKVa6AMlovCN2Rjfz7avy_MrAC0QQ130_assertion type Assertion NP252058.RAUL-FYGd_siR69BPKVa6AMlovCN2Rjfz7avy_MrAC0QQ130_head.
- NP252058.RAUL-FYGd_siR69BPKVa6AMlovCN2Rjfz7avy_MrAC0QQ130_assertion description "[RI-HER2 was significantly more frequent in tumors with two or more recurrences (40.7% versus 15.8%, P = 0.010) and in those with carcinoma in situ (CIS) (35.4% versus 15.9%, P = 0.029).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP252058.RAUL-FYGd_siR69BPKVa6AMlovCN2Rjfz7avy_MrAC0QQ130_provenance.
- NP252058.RAUL-FYGd_siR69BPKVa6AMlovCN2Rjfz7avy_MrAC0QQ130_assertion evidence source_evidence_literature NP252058.RAUL-FYGd_siR69BPKVa6AMlovCN2Rjfz7avy_MrAC0QQ130_provenance.
- NP252058.RAUL-FYGd_siR69BPKVa6AMlovCN2Rjfz7avy_MrAC0QQ130_assertion SIO_000772 15351620 NP252058.RAUL-FYGd_siR69BPKVa6AMlovCN2Rjfz7avy_MrAC0QQ130_provenance.
- NP252058.RAUL-FYGd_siR69BPKVa6AMlovCN2Rjfz7avy_MrAC0QQ130_assertion wasDerivedFrom befree-20140225 NP252058.RAUL-FYGd_siR69BPKVa6AMlovCN2Rjfz7avy_MrAC0QQ130_provenance.
- NP252058.RAUL-FYGd_siR69BPKVa6AMlovCN2Rjfz7avy_MrAC0QQ130_assertion wasGeneratedBy ECO_0000203 NP252058.RAUL-FYGd_siR69BPKVa6AMlovCN2Rjfz7avy_MrAC0QQ130_provenance.